论文部分内容阅读
目的评估急性心肌梗死(AMI)合并2型糖尿病(T2DM)溶栓治疗疗效及其影响因素的分析。方法100例AMI住院患者按照有无糖尿病史分为糖尿病组(n=32)和非糖尿病组(n=68),均在发病12小时内进行尿激酶溶栓治疗,比较两组近期疗效并分析其影响因素。结果(1)DM组的血管再通率明显低于非DM组(39.5%vs67.6%,P<0.05)。(2)与非DM组比较,DM组的空腹血糖(11.2±2.9mmol/Lvs5.4±1.3mmol/L,P<0.05)、高血压(53.1%vs48.5%,P<0.05)、高血脂(62.5%vs58.8%)、心源性休克(15.63%vs10.29%,P<0.05)、出血(9.38%vs5.88%,P<0.05)及死亡率(18.75%vs10.29%,P<0.05)显著升高。结论静脉溶栓治疗急性心肌梗死伴T2DM的近期疗效较差,高血糖、高血压、高血脂是其重要影响因素。
Objective To evaluate the efficacy and influencing factors of thrombolytic therapy in patients with acute myocardial infarction (AMI) complicated with type 2 diabetes mellitus (T2DM). Methods One hundred patients with AMI were divided into diabetic group (n = 32) and non-diabetic group (n = 68) according to the presence or absence of diabetes mellitus. Thrombolytic therapy with urokinase was performed within 12 hours after onset. The short- Its influencing factors. Results (1) The revascularization rate of DM group was significantly lower than that of non-DM group (39.5% vs67.6%, P <0.05). (2) The fasting blood glucose (11.2 ± 2.9mmol / L vs 5.4 ± 1.3mmol / L, P <0.05), hypertension (53.1% vs48.5%, P <0.05) (62.5% vs58.8%), cardiogenic shock (15.63% vs10.29%, P <0.05), hemorrhage (9.38% vs5.88%, P <0.05) and mortality (18.75% vs10.29% , P <0.05) increased significantly. Conclusion Intravenous thrombolytic therapy of acute myocardial infarction with T2DM is less effective in the short term. Hyperglycemia, hypertension and hyperlipidemia are the important influential factors.